Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 29337E102 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
FMR LLC
13G/A
Amendment 3
|
15.0% |
8/6/2026
Event 6/30/2026
|
|
| FMR LLC | 15.0% | ||
| Abigail P. Johnson | 15.0% | ||
|
Orbimed Advisors LLC
13D/A
Amendment 5
|
9.5% |
6/24/2026
Event 6/22/2026
|
|
| Orbimed Advisors LLC | 9.5% | ||
| Orbimed Capital GP VII LLC | 9.2% | ||
| Orbimed Genesis GP LLC | 0.3% | ||
| Orbimed Capital LLC | 0% | ||
|
Polar Capital Holdings Plc
13G/A
Amendment 3
|
8.5% |
6/22/2026
Event 3/31/2026
|
|
| Polar Capital Holdings Plc | 8.5% | ||
| Polar Capital LLP | 8.5% | ||
| Polar Capital Funds PLC - Biotechnology Fund | 8.5% | ||
|
Orbimed Advisors LLC
13D/A
Amendment 4
|
10.9% |
6/17/2026
Event 6/15/2026
|
|
| Orbimed Advisors LLC | 10.9% | ||
| Orbimed Capital GP VII LLC | 10.6% | ||
| Orbimed Genesis GP LLC | 0.4% | ||
| Orbimed Capital LLC | <0.1% | ||
|
Commodore Capital LP
13G/A
Amendment 4
|
7.7% |
5/15/2026
Event 3/31/2026
|
|
| Commodore Capital LP | 7.7% | ||
| Commodore Capital Master LP | 7.7% | ||
| Robert Egen Atkinson | 7.7% | ||
| Michael Kramarz | 7.7% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 4
|
2.8% |
5/15/2026
Event 3/31/2026
|
|
| Venrock Healthcare Capital Partners III, L.P. | 2.8% | ||
| VHCP Co-Investment Holdings III, LLC | 2.8% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 2.8% | ||
| VHCP Management III, LLC | 2.8% | ||
| VHCP Management EG, LLC | 2.8% | ||
| Nimish Shah | 2.8% | ||
| Bong Y. Koh | 2.8% | ||
|
Polar Capital Holdings Plc
13G/A
Amendment 2
|
8.5% |
5/15/2026
Event 3/31/2026
|
|
| Polar Capital Holdings Plc | 8.5% | ||
| Polar Capital LLP | 8.5% | ||
| Polar Capital Funds PLC - Biotechnology Fund | 8.5% | ||
|
Polar Capital Holdings Plc
13G/A
Amendment 1
|
8.5% |
5/15/2026
Event 3/31/2026
|
|
| Polar Capital Holdings Plc | 8.5% | ||
| Polar Capital LLP | 8.5% | ||
| Polar Capital Funds PLC - Biotechnology Fund | 8.5% | ||
|
Fairmount Funds Management LLC
13G/A
Amendment 5
|
3.1% |
5/15/2026
Event 3/31/2026
|
|
| Fairmount Funds Management LLC | 3.1% | ||
| Fairmount Healthcare Fund II L.P. | 3.1% | ||
| Peter Harwin | 3.1% | ||
| Kiselak Tomas | 3.1% | ||
|
Vestal Point Capital, LP
13G/A
Amendment 1
|
5.4% |
5/15/2026
Event 3/31/2026
|
|
| Vestal Point Capital, LP | 5.4% | ||
| Ryan Wilder | 5.4% | ||
|
Vestal Point Capital, LP
13G
|
6.5% |
2/17/2026
Event 12/31/2025
|
|
| Vestal Point Capital, LP | 6.5% | ||
| Ryan Wilder | 6.5% | ||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
Amendment 3
|
5.4% |
11/14/2025
Event 9/30/2025
|
|
| Venrock Healthcare Capital Partners III, L.P. | 5.4% | ||
| VHCP Co-Investment Holdings III, LLC | 5.4% | ||
| Venrock Healthcare Capital Partners EG, L.P. | 5.4% | ||
| VHCP Management III, LLC | 5.4% | ||
| VHCP Management EG, LLC | 5.4% | ||
| Nimish Shah | 5.4% | ||
| Bong Y. Koh | 5.4% | ||
|
FMR LLC
13G/A
Amendment 2
|
13.3% |
11/5/2025
Event 9/30/2025
|
|
| FMR LLC | 13.3% | ||
| Abigail P. Johnson | 13.3% | ||
|
Commodore Capital LP
13G/A
Amendment 3
|
9.9% |
8/14/2025
Event 6/30/2025
|
|
| Commodore Capital LP | 9.9% | ||
| Commodore Capital Master LP | 9.9% | ||
| Robert Egen Atkinson | 9.9% | ||
| Michael Kramarz | 9.9% | ||
|
Polar Capital Holdings Plc
13G
|
5.2%
Checked 5% or less
|
8/14/2025
Event 6/30/2025
|
|
| Polar Capital Holdings Plc | 5.2% | ||
| Polar Capital LLP | 5.2% | ||
| Polar Capital Funds PLC - Biotechnology Fund | 5.2% | ||
|
Fairmount Funds Management LLC
13G/A
Amendment 4
|
6.3% |
8/14/2025
Event 6/30/2025
|
|
| Fairmount Funds Management LLC | 6.3% | ||
| Fairmount Healthcare Fund II L.P. | 6.3% | ||
| Peter Harwin | 6.3% | ||
| Tomas Kiselak | 6.3% | ||
| BlackRock, Inc. 13G/A Amendment 1 | 5.1% |
7/17/2025
Event 6/30/2025
|
|
|
Orbimed Advisors LLC
13D/A
Amendment 3
|
13.4% |
6/17/2025
Event 6/16/2025
|
|
| Orbimed Advisors LLC | 13.4% | ||
| Orbimed Capital GP VII LLC | 13.0% | ||
| Orbimed Genesis GP LLC | 0.4% | ||
| Orbimed Capital LLC | 0.1% | ||
|
Polar Capital Holdings Plc
13G/A
Amendment 1
|
4.9% |
2/14/2025
Event 12/31/2024
|
|
| Polar Capital Holdings Plc | 4.9% | ||
| Polar Capital LLP | 4.9% | ||
| Polar Capital Funds PLC - Biotechnology Fund | 4.9% | ||
|
Fairmount Funds Management LLC
13G/A
Amendment 3
|
6.6% |
2/14/2025
Event 12/31/2024
|
|
| Fairmount Funds Management LLC | 6.6% | ||
| Fairmount Healthcare Fund II L.P. | 6.6% | ||
| Peter Harwin | 6.6% | ||
| Tomas Kiselak | 6.6% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 4 | 3.04 k | $139 k |
| 2026 Q2 | 222 | 83.2 M | $4.13 B |
| 2026 Q1 | 185 | 63.2 M | $2.46 B |
| 2025 Q4 | 132 | 62.4 M | $961 M |
| 2025 Q3 | 138 | 59.4 M | $1.22 B |
| 2025 Q2 | 129 | 59.5 M | $1.19 B |
| 2025 Q1 | 127 | 49.9 M | $984 M |
| 2024 Q4 | 118 | 49.6 M | $1.12 B |
| 2024 Q3 | 107 | 47.7 M | $1.22 B |
| 2024 Q2 | 103 | 49.0 M | $1.15 B |
| 2024 Q1 | 78 | 44.6 M | $783 M |
| 2023 Q4 | 66 | 39.1 M | $542 M |
| 2023 Q3 | 64 | 39.1 M | $534 M |
| 2023 Q2 | 65 | 39.1 M | $798 M |
| 2023 Q1 | 48 | 33.6 M | $735 M |